About
Innovation
Team
Clinical Studies
Careers
News
Publications
Contact
If we pull together collectively, we will achieve our goals
News
20.09.23
FDA Grants US Orphan Drug Designation to Medannex’s First-in-Class Therapy MDX-124
21.08.23
Medannex Announces First Patient Treated in Phase 1b Clinical Study of Groundbreaking Anti-Annexin-A1 Therapy
24.04.23
Medannex’s First-in-class Therapy Awarded UK ‘Innovation Passport’ to Accelerate Time to Market
01.03.23
MDX-124 receives Orphan Designation from the EMA for the Treatment of Pancreatic Cancer
03.01.23
Medannex features in global pharmaceutical publication ‘Scrip’
12.12.22
Regulators give green light to first-in-human study with MDX-124
1
2
3
4
5
»